Cytokine with pro- and anti-inflammatory properties, that can regulate T helper cell development, suppress T-cell proliferation, stimulate cytotoxic T cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells.
Among its target cells are CD4 T helpercells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17).
It drives rapid clonal expansion of naive but not memory CD4 T-cells.
It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naiveCD4 T-cells, binds to the cytokine receptor WSX-1/TCCR which appears to be required but not sufficient for IL-27-mediated signal transduction.
IL-27 potentiate the early phase of TH1 response and suppress TH2 and TH17differentiation.
It induces the differentiation of TH1 cells via two distinct pathways, p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways.
It also induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet via STAT1 with resulting IL12RB2 upregulation, an event crucial to TH1 cell commitment.
Itsuppresses the expression of GATA3, the inhibitor TH1 cells development.
In CD8 T-cells, it activates STATs as well as GZMB.
IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production.
Indeed IL-27 subunit p28 alone is also able to inhibit the production of IL17 byCD4 and CD8 T-cells.
While IL-27 suppressed the development of proinflammatory Th17 cells via STAT1, it inhibits the development of anti-inflammatory inducible regulatory T-cells, iTreg, independently of STAT1.
IL-27 has also an effect on cytokine production, it suppressesproinflammatory cytokine production such as IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling such as SOCS1 and SOCS3.
Apart from suppression of cytokine production, IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T cells
Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines such as IP-10/CXCL10 and MIG/CXCL9.
In vein endothelial cells, it induces IRF1/interferon regulatory factor 1 and increase theexpression of MHC class II transactivator/CIITA with resultingup-regulation of major histocompatibility complex class II.
IL-27 also demonstrates antiviral activity with inhibitory properties on HIV-1 replivation.
Applications:Suitable for use in Western Blot and ELISA.
Other applications not tested.
Recommended Dilution:Western Blot: 1:500-1:2000ELISA (peptide): 1:20,000-1:40,000Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4°C for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20°C.
Aliquots are stable for 12 months after receipt.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：100ul
Host：rabbit
Source Antibody：human
Grade：Affinity Purified
Purity：Purified by immunoaffinity chromatography.
Form：Supplied as a liquid in PBS, pH 7.4, 0.02% sodium azide, 50% glycerol.
Specificity：Recognizes endogenous levels of total human IL27A. Species Crossreactivity: mouse
Isotype：IgG
Calc Applications Abbrev：E WB
Calc Crossreactivity：Hu Mo
Immunogen：Synthetic peptide corresponding to human IL27A.
